We also found that a panel of proteins, BCL-2, HER2, CD133, CAIX, and ERCC1, can be predictors of overall survival in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT) by calculating risk scores, which were the sum of estimated coefficients from age, cancer stage, and the protein panel (14). This evidence concerns the gene CA9 and cervical cancer.